Suppr超能文献

药剂师在成人镰状细胞病管理中的作用:叙述性综述

Roles of Pharmacists in the Management of Sickle Cell Disease in Adults: A Narrative Review.

作者信息

Weaver Salome Bwayo, Nonyel Nkem P, Rungkitwattanakul Dhakrit

机构信息

Clinical and Administrative Pharmacy Sciences, College of Pharmacy, Howard University, Washington, DC, USA.

出版信息

J Pharm Technol. 2024 Apr;40(2):92-99. doi: 10.1177/87551225231222437. Epub 2024 Jan 10.

Abstract

Sickle cell disease (SCD) is an autosomal, recessive, genetic condition of the sickle cell genes. It affects about 100 000 people in the United States where an estimated 1 out of every 365 black children and 1 out of every 13 black children will be born with SCD and sickle cell trait, respectively. Severe and unpredictable pain crisis are the leading cause of emergency department visit for adult patients with SCD and account for 90% of inpatient hospitalizations and 85% of all acute medical care, as well as high usage of medical resources. The care of patients with SCD is complex and requires a multidisciplinary approach. With a few pharmacotherapeutic options to reduce SCD complications and pain episodes, the role of pharmacists in the medication management is unclear. This article aims to outline the potential role of pharmacists in SCD management. The authors searched Medline, PubMed, EMBASE, and Scopus from January 1, 1990 to August 31, 2022, for primary literature that assessed the role of pharmacists in managing patients with SCD. The authors identified relevant studies and summarized the role of pharmacists in SCD management. Access to comprehensive health care is essential to ensure that patients with SCD have decreased hospitalizations and good health-related quality of life. Pharmacists are an integral part of the multidisciplinary health-care team and can help patients with SCD navigate the complexities of health care. Pharmacists are medication experts who are positioned to ensure comprehensive care in the acute and chronic SCD management.

摘要

镰状细胞病(SCD)是一种由镰状细胞基因引起的常染色体隐性遗传病。在美国,约有10万人受其影响,估计每365名黑人儿童中就有1人、每13名黑人儿童中就有1人分别患有SCD和镰状细胞性状。严重且不可预测的疼痛危机是成年SCD患者前往急诊科就诊的主要原因,占住院治疗的90%以及所有急性医疗护理的85%,同时还导致医疗资源的高消耗。SCD患者的护理工作复杂,需要多学科方法。由于减少SCD并发症和疼痛发作的药物治疗选择有限,药剂师在药物管理中的作用尚不明确。本文旨在概述药剂师在SCD管理中的潜在作用。作者检索了1990年1月1日至2022年8月31日期间的Medline、PubMed、EMBASE和Scopus数据库,以查找评估药剂师在管理SCD患者中作用的原始文献。作者确定了相关研究,并总结了药剂师在SCD管理中的作用。获得全面的医疗保健对于确保SCD患者减少住院次数并拥有良好的健康相关生活质量至关重要。药剂师是多学科医疗团队不可或缺的一部分,可以帮助SCD患者应对复杂的医疗保健问题。药剂师是药物专家,有能力在SCD的急性和慢性管理中确保提供全面护理。

相似文献

1
Roles of Pharmacists in the Management of Sickle Cell Disease in Adults: A Narrative Review.
J Pharm Technol. 2024 Apr;40(2):92-99. doi: 10.1177/87551225231222437. Epub 2024 Jan 10.
2
Interventions for chronic kidney disease in people with sickle cell disease.
Cochrane Database Syst Rev. 2017 Jul 3;7(7):CD012380. doi: 10.1002/14651858.CD012380.pub2.
3
Interventions for chronic kidney disease in people with sickle cell disease.
Cochrane Database Syst Rev. 2023 Aug 4;8(8):CD012380. doi: 10.1002/14651858.CD012380.pub3.
4
Surveillance for Sickle Cell Disease - Sickle Cell Data Collection Program, Two States, 2004-2018.
MMWR Surveill Summ. 2022 Oct 7;71(9):1-18. doi: 10.15585/mmwr.ss7109a1.
5
Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Cochrane Database Syst Rev. 2022 Sep 1;9(9):CD002202. doi: 10.1002/14651858.CD002202.pub3.
6
Preoperative blood transfusions for sickle cell disease.
Cochrane Database Syst Rev. 2020 Jul 2;7(7):CD003149. doi: 10.1002/14651858.CD003149.pub4.
7
Folate supplementation in people with sickle cell disease.
Cochrane Database Syst Rev. 2018 Mar 16;3(3):CD011130. doi: 10.1002/14651858.CD011130.pub3.
8
Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults.
Cochrane Database Syst Rev. 2019 Nov 14;2019(11):CD012187. doi: 10.1002/14651858.CD012187.pub2.
9
A review of the literature on the multiple dimensions of chronic pain in adults with sickle cell disease.
J Pain Symptom Manage. 2010 Sep;40(3):416-35. doi: 10.1016/j.jpainsymman.2009.12.027. Epub 2010 Jul 24.
10
Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease.
Cochrane Database Syst Rev. 2020 Mar 3;3(3):CD012762. doi: 10.1002/14651858.CD012762.pub2.

本文引用的文献

1
CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022.
MMWR Recomm Rep. 2022 Nov 4;71(3):1-95. doi: 10.15585/mmwr.rr7103a1.
3
Advances in the diagnosis and treatment of sickle cell disease.
J Hematol Oncol. 2022 Mar 3;15(1):20. doi: 10.1186/s13045-022-01237-z.
4
Transition from Oxycodone to Buprenorphine/Naloxone in a Hospitalized Patient with Sickle Cell Disease: A Case Report.
J Gen Intern Med. 2022 Apr;37(5):1281-1285. doi: 10.1007/s11606-021-07295-2. Epub 2022 Jan 6.
6
Contemporary Management and Prevention of Vaso-Occlusive Crises (VOCs) in Adults With Sickle Cell Disease.
J Pharm Pract. 2023 Feb;36(1):139-148. doi: 10.1177/08971900211026644. Epub 2021 Jun 21.
7
The Role of the Pharmacist in the Care of Patients with Chronic Pain.
Integr Pharm Res Pract. 2021 Apr 30;10:33-41. doi: 10.2147/IPRP.S248699. eCollection 2021.
9
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
N Engl J Med. 2021 Jan 21;384(3):252-260. doi: 10.1056/NEJMoa2031054. Epub 2020 Dec 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验